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Coronary stents are the mainstay of percutaneous coronary revascularization procedures and have significantly
decreased the rates of acute vessel closure and restenosis. Stent thrombosis (ST) after percutaneous coronary
intervention is an uncommon and potentially catastrophic event that might manifest as myocardial infarction
and sudden death. Optimization of stent implantation and dual antiplatelet therapy have markedly reduced the
occurrence of this complication. Bare-metal stent (BMS) thrombosis occurs in 1% of the cases, usually within
the first month after implantation. The advent of drug-eluting stents (DES) has raised concerns regarding
later occurrence of ST, beyond the traditional 1-month timeframe, especially in complex lesion subsets that
were excluded from randomized trials that compared BMS to DES. There is widespread controversy regard-
ing the actual incremental risk associated with DES. Recent studies suggest a 0.5% increased long-term
thrombosis risk with DES; however, the clinical significance of these events remains under debate. The de-
gree of protection achieved by dual antiplatelet therapy and optimal duration of treatment are under inves-
tigation. Novel stent designs might potentially decrease the incidence of this event. In this review, we will
describe the current knowledge of the pathophysiology of late DES thrombosis, although many aspects re-
main incompletely understood. (J Am Coll Cardiol 2007;50:119–27) © 2007 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.031a
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soronary stents are the mainstay of percutaneous coronary
evascularization procedures and have significantly de-
reased the rates of acute vessel closure and restenosis. Stent
hrombosis (ST) after percutaneous coronary intervention
PCI) is an uncommon and potentially catastrophic event
hat might manifest as myocardial infarction (MI) and
udden death. Optimization of stent implantation and dual
ntiplatelet therapy have markedly reduced the occurrence
f this complication. Bare-metal stent (BMS) thrombosis
ccurs in 1% of the cases, usually within the first month
fter implantation. The advent of drug-eluting stents (DES)
as raised concerns regarding later occurrence of ST, be-
ond the traditional 1-month timeframe, especially in com-
lex lesion subsets that were excluded from randomized
rials that compared BMS to DES. There is widespread
ontroversy regarding the actual incremental risk associated
ith DES. Recent studies suggest a 0.5% increased long-
erm thrombosis risk with DES (1,2); however, the clinical
ignificance of these events remains under debate (3). The
egree of protection achieved by dual antiplatelet therapy
rom the Schulich Heart Program, Sunnybrook Health Sciences Centre, University
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007, accepted April 2, 2007.nd optimal duration of treatment are under investigation.
ovel stent designs might potentially decrease the incidence
f this event. In this review, we will describe the current
nowledge of the pathophysiology of late DES thrombosis,
lthough many aspects remain incompletely understood.
efinition and Clinical Manifestations
istorically, diagnosis of ST has been based on angio-
raphic and clinical criteria. Angiographic definition—
oronary Thrombolysis In Myocardial Infarction flow grade
to 1 in the stented vessel in the presence of thrombus—
ikely underestimates the true incidence of ST, because
atients who are asymptomatic or who sustain cardiac arrest
ight not undergo coronary angiography. Clinical defini-
ions—target vessel MI or urgent target lesion revascular-
zation and unexplained sudden death when the stent was
ot known to be patent—might overestimate the actual
ccurrence of ST. The recently proposed “Academic Re-
earch Consortium” definitions (4) were designed to stan-
ardize ST diagnosis and provide consistency in the report-
ng of future trials (Table 1).
Stent thrombosis is also classified according to the time
lapsed since implantation. Acute ST occurs during the
tenting procedure or within the subsequent 24 h, subacute
T between 1 and 30 days after implant, late ST between 1
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ST occurs more than 1 year after
the procedure. In the BMS era,
ST usually presented acutely or
subacutely, before neointimal
formation. In randomized trials
that compared BMS with DES,
rates of acute and subacute ST
among patients receiving dual anti-
platelet therapy were similar for
both stent types (1%) (3,5). Re-
cent attention has focused on de-
layed occurrence ofDES thrombosis
beyond 30 days, which might be
ategorized according to the intensity of antiplatelet therapy
dministered at the time of the event, while the patient is
till receiving dual antiplatelet therapy or after cessation of 1
r both antiplatelet drugs.
Acute and subacute thrombosis of both BMS and DES
ave adverse clinical consequences (6,7). In a registry of
atients who underwent DES implantation with 9-month
ollow-up (8), 24% of ST cases presented as death, 60% as
onfatal MI, and 7% as unstable angina. The case fatality
ate for ST in this registry was 45%. In a series of patients
ho presented with acute coronary syndrome and had
ngiographically or autopsy proven ST after DES implan-
ation, 6-month mortality was 31% (9). However, in recent
eta-analyses of DES trials, modest increases in rates of
ate and very late ST compared with BMS did not translate
nto a worse clinical outcome (3,10). These differences
ight reflect selection bias stemming from different diag-
ostic criteria for ST or possibly from implantation of DES
n small vessels subtending limited myocardial territory.
ercutaneous coronary intervention for emergent ST is
ften suboptimal, and ST recurs in 12% of these patients
11).
ncidence of Late and
ery Late Stent Thrombosis
ate BMS thrombosis is an uncommon event (12). In an
nitial report of very late DES thrombosis, the events were
ssociated with cessation of antiplatelet therapy (13). Sub-
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
tent Thrombosis Definitions and Classification
Table 1 Stent Thrombosis Definitions and Classification
“Academic Research Consortium” definitions (4)
Definite ST Acute coro
Probable ST 1. Unexpla
2. Acute m
Possible stent thrombosis All unexpla
Temporal classification
Acute ST During PCI
Subacute ST Between 1
Late ST Between 1
Very late ST More thanCI  percutaneous coronary intervention; ST  stent thrombosis.equently, studies of patients who underwent DES implan-
ation for off-label indications in complex anatomical sub-
ets, with prolonged follow-up periods, have documented
igher ST rates than previously reported (14–16).
Recently reported registries, randomized trials, and meta-
nalyses have investigated the relative risk for late ST with
ither DES or BMS over varying follow-up periods and
eported conflicting results. Some studies identified
hrombosis-related clinical events, whereas others focused
n angiographically proven ST. In a registry of 6,906
atients who received BMS or DES, there was no difference
n clinical outcomes or ST rate over 1 year of follow-up (17).
n another registry of 8,146 patients who received DES
etween 2002 and 2005, a persistent excess ST risk of
.6%/year was found compared with historical control
ubjects who received BMS (2). A meta-analysis of 8 trials
n which 4,545 patients were randomized to sirolimus-
luting stent (SES) or paclitaxel-eluting stent (PES) versus
MS revealed no difference in rates of ST over 4 years of
ollow-up (5). Conversely, another meta-analysis of 14
andomized clinical trials, in which a total of 6,675 patients
ere randomized to either SES or PES versus BMS,
onfirmed a 0.5% excess risk of very late ST with DES (1).
Several recent studies have highlighted the potential
dverse clinical significance of late thrombotic events. In a
wedish registry of DES and BMS patients, the adjusted
elative risk for death associated with DES implantation
rom 6 months to 3 years after PCI was 1.32 (95%
onfidence interval 1.11 to 1.57) (18). The authors hypoth-
sized that ST caused the increased mortality. In the
ASKET-LATE (Basel Stent Kosten Effektivitäts Trial–
ate Thrombotic Events) study, 746 patients who had been
andomized to DES or BMS and were free of major cardiac
dverse events after 6 months (when clopidogrel was
topped) were followed for an additional 12 months (19).
uring this follow-up period, rates of cardiac death and
onfatal MI were higher in the DES than the BMS group
4.9% vs. 1.3%, respectively). However, this increase in
ajor cardiac events in the DES group was much higher
han the actual difference in the rates of definite or possible
T (2.6% DES group vs. 1.3% BMS group). Timing of
hrombotic events was evenly distributed across the 12
ndrome with angiographic or autopsy evidence of thrombus or occlusion
aths within 30 days following PCI
ial infarction involving the target-vessel territory without angiographic confirmation
eaths occurring at least 30 days following PCI
in the following 24 h
0 days following PCI
and 1 yr following PCI
llowing PCInary sy
ined de
yocard
ined d
or with
and 3
month
1 yr fo
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July 10, 2007:119–27 Late and Very Late Stent Thrombosisonths after clopidogrel discontinuation. Camenzind et al.
20) reported a meta-analysis of randomized trials compar-
ng DES with BMS that included 5,108 patients, with
ollow-up over 9 months to 3 years; SES were associated
ith a 60% relative increase in death or MI (p  0.03),
hereas PES were associated with a nonsignificant increase
f 15%. Another meta-analysis of 9 trials in which 5,261
atients were randomized to SES, PES, or BMS reached
uite different conclusions (3). Over 4 years of follow-up,
ncreased rates of very late ST were found both for both
ES (0.6% vs. 0%, p  0.025) and PES (0.7% vs. 0.2%, p
0.028) compared with BMS. The increased ST rate was
onfined to the time interval between 1 month and 1 year
fter PCI and was not associated with adverse clinical
utcomes. Similarly, a meta-analysis of 14 trials in which
,958 patients were randomized to SES or BMS, with
ollow-up ranging up to 59 months, showed an increased
ate of very late ST with SES (0.6% vs. 0.05%, p  0.02)
ithout increase in adverse events (10).
echanisms Contributing to ST:
re There Differences Between BMS and DES?
fter both BMS and DES implantation, procedural and
echnical factors play a major role in determining the
ccurrence of acute and subacute ST, whereas delayed
hrombotic events seem to be influenced largely by the
egree of endothelial coverage and intensity of antiplatelet
herapy (21). Incomplete endothelization and presence of
hrombus were frequent angioscopic findings in a study
erformed 3 to 6 months after DES implantation but were
ot found in BMS (22). Presence of lipid-rich plaques
bundant in tissue factor within the vessel wall might
redispose to late ST (12).
Data regarding risk factors for DES thrombosis are
erived from selected case reports, non-randomized regis-
ries (Table 2), and randomized clinical trials (23–27)
Table 3). Evidence for increased long-term ST risk with
ES is primarily from patient registries and not from
andomized clinical trials, suggesting that part of the incre-
ental risk is associated with treatment of complex coronary
esions in real-world patients (Table 4).
atient variables. Angioplasty in the setting of acute
oronary syndromes could theoretically predispose to ST
wing to the large thrombotic burden already present,
uboptimal stent expansion to avoid the risk of no-reflow, or
ES implantation on a thrombus that eventually disappears
eading to malapposition. An SES registry reported in-
reased risk of ST in patients who presented with acute
oronary syndromes (28). However, 3 randomized trials
omparing BMS and DES for primary angioplasty in acute
I found no difference in ST rate between the stent types
29–31). Some registry reports have suggested increased ST
ates in diabetic patients and patients with renal failure
8,9,28). arocedural variables. Small vessel size, long stents, subop-
imal stent expansion, residual dissections and thrombus,
nd slow coronary flow are associated with DES thrombosis
9,28,32,33), similar to BMS. A 1.03-fold greater ST risk
or every 1-mm increase in stent length has been calculated
34). Reports of higher ST rates in bypass grafts treated with
ES compared with BMS (19) were not confirmed in a
andomized trial (35). Drug-eluting stents have permitted
n aggressive approach to angioplasty of bifurcation lesions,
hich is associated with higher rates of ST (36). In a
egistry of patients undergoing stenting with BMS or DES,
ifurcation stenting in the setting of acute MI was an
ndependent risk factor for ST (odds ratio 13) (7). In
nother DES registry, bifurcation stenting was associated
ith a 3.6% to 3.9% ST rate, depending on whether 1 or 2
tents were implanted (8). A registry of “crush” bifurcation
tenting with DES reported that 4.3% of the patients had an
vent consistent with possible ST over 9 months of
ollow-up (16). In a randomized trial that compared im-
lantation of 1 versus 2 SES in coronary bifurcations, 3.5%
f the patients had ST and another patient died suddenly,
ll of whom had undergone implantation of 2 stents (14).
ntiplatelet therapy. Cessation of antiplatelet therapy is a
ajor risk factor for late BMS thrombosis. In a series of
ngiographically documented cases of late DES thrombosis,
o cases occurred in patients who were receiving dual
ntiplatelet therapy (37). In another study of DES throm-
osis within 9 months of stenting (14 subacute ST, 15 late
T), the most important independent predictor of ST was
remature antiplatelet therapy discontinuation (hazard ratio
0) (8). In a registry of bifurcation “crush” stenting with
ES, premature discontinuation of dual antiplatelet therapy
as associated with occurrence of subacute and late ST
odds ratio 17) (15). In a registry of 4,666 patients who
nderwent PCI, prolonged use of clopidogrel was associated
ith decreased risk of death or MI after implantation of
ES but not BMS (38).
Premature discontinuation of antiplatelet agents might be
elatively common: among 500 patients who received DES
fter MI, 13.6% stopped thienopyridine therapy within 30
ays (39). Patients who prematurely stopped thienopyridine
herapy had more comorbidities, lower socioeconomic sta-
us, and were less informed about the importance of
ong-term therapy than patients continuing therapy. These
atients were also more likely to die during the next 11
onths (7.5% vs. 0.7%) and be rehospitalized (23% vs.
4%).
Inadequate response to antiplatelet therapy might be caused
y patient non-compliance, underdosing, drug interactions,
omorbidities that affect the drug-response, genetic polymor-
hisms at the receptor level, or upregulation of other platelet
ctivation pathways (40,41). Several studies have suggested a
ole for clopidogrel resistance in the pathogenesis of subacute
T in BMS (42,43). In a cohort of patients undergoing
on-emergent PCI (75% DES), high preprocedural platelet
ggregation was associated with an increased risk for postpro-
Rates of Stent Thrombosis in Patient Registries
Table 2 Rates of Stent Thrombosis in Patient Registries
Reference
No. of
Patients
Study
Design Stent Type
Antiplatelet
Medication
Duration of
Dual
Antiplatelet
Therapy
Follow-Up
Duration ST Definition ST Rate Suggested Risk Factors
Iakovou
et al. (8)
2,229 SES registry SES 48%
PES 52%
ASA, thieno SES 2 months
PES 6 months
9 months ACS  angio, SCD or MI
after successful PCI not
clearly due to another
coronary lesion
SAT: 0.6%
LST: 0.7% (median
57 days)
Discontinuation of dual antiplatelet
therapy, renal failure, bifurc
lesions, diabetes, reduced LVEF
Ong et al. (7) 2,512 Combined
BMS &
DES
registry
BMS 20%
SES 40%
PES 40%
ASA, thieno 1 month 1 month Definite: angio
Possible: SCD or MI not
clearly due to another
coronary lesion
Definite: BMS 1.2%,
SES 1.0%, PES 1.0%
Possible: BMS 1.4%,
SES 1.5%, PES 1.6%
Bifurc stenting in the setting of
acute MI
Williams
et al. (17)
6,906 Combined
BMS &
DES
registry
BMS 6%
SES 56%
PES 38%
ASA, thieno Unspecified 12 months Definite: ACS  angio
Probable: unexplained
SCD or MI in target
vessel territory
Definite  probable:
BMS 0.8%,
SES 0.5%,
PES 0.8%
Ong et al.
(37)
2,006 DES registry
of LST
and VLST
SES 51%
PES 49%
ASA, thieno SES 2 months
PES 6 months
Mean 1.5
 0.5 yrs
ACS  angio LST: 0.25% (range
2–11 months),
VLST: 0.15% (range
14–26 months)
Kuchulakanti
et al. (9)
2,974 DES registry SES 72%
PES 28%
ASA, thieno 6 months 12 months Autopsy or angio ( ACS
if 30 days after PCI)
SAT: 0.84% (mean
9  9 days),
LST: 0.27%
(mean 153  100
days)
Renal failure, bifurc lesion, in-stent
restenosis, discontinuation of dual
antiplatelet therapy
Urban et al.
(28)
15,157 SES registry SES 100% ASA, thieno Unspecified 12 months Definite: angio or autopsy
Likely: target vessel-
related MI or death due
to ACS within 30 days
of PCI
SAT: 0.56%
LST: 0.19%
Insulin-dependent diabetes, ACS at
presentation, advanced age,
reduced coronary flow after PCI,
treatment of multiple lesions,
calcified or totally occluded lesion,
multivessel disease
Daemen
et al. (2)
8,146 DES registry SES 47%
PES 53%
ASA, thieno SES 2 months
PES 6 months
Mean 20
months
ACS  angio SAT: 1.1%,
LST: 0.3%
VLST: 0.4%
Discontinuation of dual antiplatelet
therapy
Ge et al. (15) 181 DES registry
of bifurc
“crush”
stenting
SES 59%
PES 41%
ASA, thieno 6 months 9 months ACS  angio, MI within
the stented territory,
cardiac death
SAT: 0.6%,
LST: 2.2%
Discontinuation of dual antiplatelet
therapy, advanced age
Hoye et al.
(16)
231 DES registry
of bifurc
“crush”
stenting
SES 57%
PES 43%
ASA, thieno 6 months 9 months ACS  angio, MI within
the stented territory,
cardiac death
SAT: 1.3%
LST: 3%
Discontinuation of dual antiplatelet
therapy
ACS  acute coronary syndrome; Angio  angiography; ASA  aspirin; bifurc  bifurcation; BMS  bare-metal stents; DES  drug-eluting stents; FU  follow-up; LST  late stent thrombosis; LVEF  left ventricular ejection fraction; MI  myocardial infarction; PCI 
percutaneous coronary intervention; PES  paclitaxel-eluting stents; SAT  subacute stent thrombosis; SCD  sudden cardiac death; SES  sirolimus-eluting stents; ST  stent thrombosis; thieno  thienopyridines; VLST  very late stent thrombosis.
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Rates of Stent Thrombosis in Randomized Controlled Trials and Meta-Analyses
Table 3 Rates of Stent Thrombosis in Randomized Controlled Trials and Meta-Analyses
Reference
No. of
Patients Study Design
Stent
Type Medication
Duration of
Dual
Antiplatelet
Therapy
Follow-Up
Duration ST Definition ST Rate Suggested Risk Factors
Moreno et al.
(34)
5,030 Meta-analysis:
RCT of BMS
vs. DES
BMS 48%
SES 17%
PES 34%
ASA, thieno 1–6 months 6–12 months Unspecified SAT: 0.35% (BMS  DES)
LST: 0.23% (BMS  DES)
Stent length
Bavry et al.
(23)
3,817 Meta-analysis:
RCT of BMS
vs. PES
BMS 48%
PES 52%
ASA, thieno,
cilostozal
ASA  thieno:
0–6 months
6–12 months ACS  angio SAT  LST: 0.76% (PES  BMS) Discontinuation of dual antiplatelet therapy
Morice et al.
(REALITY)
(24)
1,386 RCT of SES vs.
PES
SES 51%
PES 49%
ASA, thieno SES 2 months
PES 6 months
12 months SAT: cardiac death, MI in
stented territory
LST: MI in stented territory
with angio
SAT: SES 0.4%, PES 1.0%
LST: SES 0%, PES 0.3%
Kastrati et al.
(25)
3,669 Meta-analysis:
RCT of SES
vs. PES
SES 50%
PES 50%
ASA, thieno 2–12 months 6–13 months ACS  angio, unexplained
SCD, MI in stented
territory
SAT  LST: 1.0% (PES  SES)
Colombo et al.
(14)
85 RCT of single
vs. dual
SES for
bifurc PCI
SES
100%
ASA, thieno 3 months 6 months Probable: angio, MI or SCD
within 30 dys of PCI
Possible: SCD beyond 1
month
Probable: 3.5%,
Probable  possible: 4.5%
Dual stenting
Spalding et al.
(26)
1,748 Meta-analysis:
RCT of BMS
vs. SES
BMS 50%
SES 50%
ASA, thieno 2 months 48 months ARC: definite  probable 
possible
SAT: SES 0.5%, BMS 0.5%
LST: SES 0.3%, BMS 1.3%
(p  0.03)
VLST: SES 2.8%, PES 1.7%
Mauri et al. (5) 4,545 Meta-analysis:
RCT of BMS
vs. DES
SES 19%
PES 31%
BMS 50%
ASA, thieno SES 2 months
PES 6 months
48 months ARC: definite  probable SES vs. BMS:
SAT: SES 0.5%, BMS 0.3%
LST: SES 0.1%, BMS 1.0%
VLST: SES 0.9%, BMS 0.4%
PES vs. BMS:
SAT: PES 0.5%, BMS 0.5%
LST: PES 0.4%, BMS 0.3%
VLST: PES 0.9%, BMS 0.6%
Kastrati et al.
(10)
4,958 Meta analysis:
RCT of BMS
vs. SES
SES 50%
BMS 50%
ASA, thieno 1–12 months 12.1–58.9
months
According to definitions in
individual trial protocols
SAT  LST  VLST:
SES 1.4%, BMS 1.26%
VLST: SES 0.6%, BMS 0.05%
(p  0.02)
Continued on next page
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Table 3 Continued
Reference
No. of
Patients Study Design
Stent
Type Medication
Duration of
Dual
Antiplatelet
Therapy
Follow-Up
Duration ST Definition ST Rate Suggested Risk Factors
Pfisterer et al.
(BASKET-
LATE) (19)
746 RCT of DES
vs. BMS*
(analysis of
LST and
VLST)
SES 34%
PES 38%
BMS 38%
ASA None 12 months
after initial
6 months
follow-up
Definite: ACS  angio
Possible: all SCD and MI
attributable to the target
vessel
Definite:
DES 1.4%, BMS 0.8%
Definite  possible:
DES 2.6%, BMS 1.3%
Previous MI, increased need for glyco-
protein IIb/IIIa inhibitor, side branch,
bypass graft stenting
Ellis et al. (27) 3,445 Meta-analysis:
RCT of BMS
vs. PES
PES 50%
BMS 50%
ASA, thieno 6 months 14–41
months
ACS  angio, MI in stented
territory
SAT:
PES: 0.5%, BMS: 0.5%
LST  VLST: PES 0.5%,
BMS 0.06% (p  0.049)†
LST  VLST: major adverse cardiac
event within 30 days postprocedure
Stone et al. (3) 5,261 Meta-analysis:
RCT of BMS
vs. DES
SES 17%
PES 33%
BMS 50%
ASA, thieno SES 2 months
PES 6 months
48 months According to definitions in
individual trial protocols
SES vs. BMS:
SAT: SES 0.5%, BMS 0.1%
LST: SES 0.1%, BMS 0.5%
VLST: SES 0.6%, BMS 0%
(p  0.025)
PES vs. BMS:
SAT: PES 0.5%, BMS 0.6%
LST: PES 0.2%, BMS 0.1%
VLST: PES 0.7%, BMS 0.2%
(p  0.028)
Bavry et al. (1) 6,675
(14
trials)‡
Meta-analysis:
VLST in RCT
of BMS vs.
DES
SES 24%
PES 26%
BMS 50%
ASA None 12–36
months
beyond
first year
after PCI
ACS  angio Total cohort: DES 0.5%, BMS 0%
(p  0.02)
SES vs. BMS: SES 0.36%,
BMS 0% (p  0.22)
PES vs. BMS: PES 0.59%,
BMS 0% (p  0.49)
*Cohort of patients who survived the initial 6 months without major events were followed for 1 year after stopping thieno; †only p values  0.05 specified; ‡only 8 of the trials had more than 1-year follow-up.
ARC  Academic Research Consortium; RCT  randomized controlled trial; other abbreviations as in Table 2.
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July 10, 2007:119–27 Late and Very Late Stent Thrombosisedural ischemic events over 1 year of follow-up (44). Cross-
esistance to aspirin and clopidogrel might be common (45). In
study of elective PCI patients, 12.7% were aspirin-resistant
nd 24% were clopidogrel-resistant (46). Aspirin-resistant
atients were more likely to be women and have diabetes, and
7.4% of them were clopidogrel-resistant. An additional con-
ern regarding antagonism of cytochrome P450 3A4 metabo-
ism of clopidogrel by statins (47) has not been substantiated
48).
esponse of the vessel to DES. The intact endothelium
eparates the thrombogenic vessel wall and stent struts from
he blood stream and secretes a variety of antithrombotic
nd vasodilator substances. Drug-eluting stents expose the
essel wall to antiproliferative drugs and drug-eluting plat-
orms, with variable effects on endothelial regeneration and
unction. Rabbit iliac arterial segments in which overlapping
ES and PES were implanted exhibited delayed healing
ompared with proximal and distal non-overlapping sites
nd compared with overlapping BMS (49). However, in
uman studies, overlapping SES were not associated with
ncreased ST risk (50). Studies performed 6 months after
CI have examined endothelium-dependant arterial vaso-
otion in response to acetylcholine (51) and exercise (52).
rterial segments adjacent to SES but not BMS demon-
trated reduced endothelial function, although the clinical
ignificance of this finding is unknown.
Malapposition of the stent to the vessel wall might result
rom suboptimal stent expansion (“procedural”) or develop
onths after the PCI (“acquired”). Although procedural
alapposition is a recognized risk factor for acute and
ubacute ST (53), the clinical significance of acquired
alapposition is controversial. Acquired BMS malapposi-
ion, which is related to positive arterial remodeling, is rare
nd benign (54). Acquired DES malapposition might result
rom drug-induced inhibition of neointimal formation,
elayed reparative events that usually enable the vessel wall
o incorporate the stent, and drug-induced positive remod-
ling of the vessel wall (55). Some randomized studies
56,57) but not others (58) reported an increased rate of
cquired malapposition with DES compared with BMS,
hich was not associated with adverse events.
Late hypersensitivity reactions to DES seem to be an-
uggested Risk Factors For Late and Very Late Stent Thrombosis
Table 4 Suggested Risk Factors For Late and Very Late Stent
Patient characteristics Diabetes, acute coronary syndrome, renal f
cardiac event within 30 days of the origi
Coronary anatomy Type C lesion, bifurcation, in-stent restenos
length, bypass graft
Procedural characteristics Reduced coronary flow after stenting, stent
branch occlusion, need for glycoprotein I
Discontinuation of dual antiplatelet
therapy
Clopidogrel resistance
Hypersensitivity reaction
Delayed arterial healingther mechanism contributing to ST. Virmani et al. (59) aeported autopsy findings after late ST (18 months after
eceiving 2 SES). Angiographic and intravascular ultra-
ound (IVUS) results at 8 months had demonstrated vessel
nlargement with absence of neointimal formation. Autopsy
howed aneurysmal dilation of the stented arterial segments
ith a severe localized hypersensitivity reaction consisting
redominantly of T lymphocytes and eosinophils. Because
irolimus is minimally present in the vessel wall after 60
ays, these findings likely reflect an effect of the non-
rodable polymer (60). A subsequent pathological study
evealed that late ST after DES was correlated with delayed
ealing of the vessel wall, persistent fibrin deposition, and
elayed endothelization (55). Nebeker et al. (61) reported
7 cases of hypersensitivity reaction attributable to DES
mplantation (14 SES and 3 PES) that occurred up to 210
ays after the index procedure. Autopsies in 4 patients who
ied after ST confirmed intrastent eosinophilic inflamma-
ion, thrombosis, and lack of intimal healing. In 1 of these
atients, concomitantly placed BMS were not associated
ith these hypersensitivity findings. Clinical manifestations
ncluded urticarial and non-urticarial rash, dyspnea, myal-
ia/arthralgia, itching, and blisters. All urticarial eruptions
egan within 10 days of implantation. Laboratory findings
ncluded eosinophilia and elevated immunoglobulin E titers
-fold above normal levels in 3 patients. Clinical or labora-
ory findings did not abate with discontinuation of anti-
latelet medications.
revention
ptimization of stent deployment (62) and dual antiplatelet
herapy with aspirin and a thienopyridine (63–65) have
chieved the currently accepted 30-day ST rate of 1%.
eports of late DES thrombosis, often in association with
essation of antiplatelet therapy (9,13,19,37,38,59), suggest
hat long-term combined antiplatelet therapy might be
ppropriate. A recent science advisory has recommended
engthening the duration of dual antiplatelet therapy to 1
ear after PCI and that elective surgery should be postponed
or 1 year (66). The efficacy of increasing the maintenance
ose of clopidogrel to 150 mg daily in patients with
uspected clopidogrel resistance is unknown (67). Triple
bosis
advanced age, reduced ejection fraction, major adverse
cedure, previous myocardial infarct
(8,9,15,19,27,28)
ltivessel disease, calcification, total occlusion, stent (8,9,19,28,34)
expansion, residual dissection, “crush” technique, side
inhibitor
(14,16,19,28,32,33)
(2,8,9,15,35)
(44)
(59,61)
(55)Throm
ailure,
nal pro
is, mu
under
Ib/IIIantiplatelet therapy with aspirin, a thienopyridine, and
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Late and Very Late Stent Thrombosis July 10, 2007:119–27ilostazol was associated with reduced rate of subacute BMS
hrombosis compared with dual antiplatelet therapy (68),
lthough its role in the DES era is unknown.
Innovative stent designs that are polymer-free, bioabsorb-
ble, or coated with monoclonal antibodies that bind circu-
ating endothelial progenitor cells have been proposed to
ecrease ST rates (69). Their role in preventing late DES
hrombosis is unclear.
ate ST: Is It the Artery or the Stent?
rug-eluting stents, by significantly reducing restenosis
ates, have expanded the indications for PCI into new
omplex anatomic subsets (long lesions, small arteries,
ifurcations) in high-risk patients (renal failure, diabetes),
ho are more susceptible to both restenosis and ST. A
ecent meeting of a U.S. Food and Drug Administration
dvisory panel concluded that DES seem to carry a greater
isk of late ST than BMS, which might be associated with
ff-label use of these stents, although the magnitude of the
isk is unclear (70). This increased risk might be explained
oth by the complexity of the atherosclerotic substrate
urrently being treated as well as by intrinsic properties of
he DES themselves. By delaying vessel healing in an artery
redisposed to thrombosis and inducing a prolonged in-
ammatory response, DES effectively lengthen and amplify
he window of opportunity for ST to occur.
Because of current evidence of the modest increased risk, it
s imperative for clinicians to stratify the individual patient’s
isk for ST, restenosis, and bleeding when selecting appropriate
evascularization strategies. Specifically, if the patient is un-
ikely to comply with long-term clopidogrel therapy, is likely to
equire surgery in the near-term, or is at risk of bleeding,
lternative treatments are preferred, such as implanting BMS,
erforming bypass surgery, or managing the patients medically.
ccording to current guidelines, dual antiplatelet therapy
hould be continued for 1 year (66). Some authorities recom-
end an even longer duration of dual therapy pending further
ata (71). Ultimately, innovative pharmacological and device
evelopments to prevent late ST are required to restore full
onfidence in DES for widespread use.
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